Syncope evaluation in athletes with hypertrophic cardiomyopathy necessitates individualized risk stratification and shared decision-making to distinguish benign from life-threatening etiologies.
Highlights the importance of individualized risk stratification and shared decision-making when evaluating syncope in athletes with hypertrophic cardiomyopathy.
Absolute Event Rate: 0% vs 0%
Syncope in athletes with hypertrophic cardiomyopathy (HCM) requires careful evaluation, as etiologies range from benign to life-threatening. Guidelines emphasize individualized risk stratification and shared decision-making.
Tatapudi et al. (Sun,) reported a other. Syncope evaluation in athletes with hypertrophic cardiomyopathy necessitates individualized risk stratification and shared decision-making to distinguish benign from life-threatening etiologies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: